Goldshield's legal fees force profit warning
Your support helps us to tell the story
From reproductive rights to climate change to Big Tech, The Independent is on the ground when the story is developing. Whether it's investigating the financials of Elon Musk's pro-Trump PAC or producing our latest documentary, 'The A Word', which shines a light on the American women fighting for reproductive rights, we know how important it is to parse out the facts from the messaging.
At such a critical moment in US history, we need reporters on the ground. Your donation allows us to keep sending journalists to speak to both sides of the story.
The Independent is trusted by Americans across the entire political spectrum. And unlike many other quality news outlets, we choose not to lock Americans out of our reporting and analysis with paywalls. We believe quality journalism should be available to everyone, paid for by those who can afford it.
Your support makes all the difference.Mounting lawyers' fees have triggered a profit warning from Goldshield, the Croydon-based drug manufacturer being sued by the Department of Health and investigated by the Serious Fraud Office.
In a statement, the group said it had experienced "higher than anticipated costs" and told analysts that the battle with the Government was proving particularly expensive. The department is demanding £28m in compensation from Goldshield and three other companies over allegations of price-fixing. The companies are accused of breaching competition law to inflate the price of warfarin, an anti-coagulant, to the NHS. Analysts were told the transfer of call centres to India and the launch of a new cable TV channel advertising Goldshield's mail-order vitamins have also proved more expensive.
The lawsuit follows the Government's decision to call in the SFO to investigate the price of warfarin. Goldshield's offices and the home of its chairman, Ajit Patel, were raided by the SFO in April. The group's shares have lost three-quarters of their value since then, and were off 15p to 120p yesterday. Goldshield denies that it acted to inflate the price of warfarin, and has vowed to fight the claim.
Join our commenting forum
Join thought-provoking conversations, follow other Independent readers and see their replies
Comments